

Diese Meldung kann unter <http://www.presseportal.de/pm/64962/1194689/inovelon-r-a-new-treatment-for-lennox-gastaut-syndrome-reduces-drop-attacks-by-over-40> abgerufen werden.

# Eisai Europe Limited

Inovelon(R) a New Treatment for Lennox-Gastaut Syndrome Reduces Drop Attacks by Over 40%

20.05.2008 - 11:18 Uhr, Eisai Europe Limited

London (ots/PRNewswire) - - First EMEA Licensed Treatment Specifically for LGS Offers New Hope for Patients With Epilepsy

Eisai Europe Limited, (Headquarters: London, Chairman and CEO Yutaka Tsuchiya) today announced publication of the results of a major study of its new anti-epileptic agent Inovelon (rufinamide) indicated for adjunctive therapy in Lennox-Gastaut Syndrome (LGS), a severe form of generalised epilepsy that develops in early childhood.

In the placebo-controlled study, published in the journal Neurology, Inovelon was found to produce a median reduction in seizure frequency of 42.5% (p=

Originaltext:

Eisai Europe Limited

Pressemappe:

<http://www.presseportal.de/pm/64962/eisai-europe-limited>

Pressemappe als RSS:

[http://presseportal.de/rss/pm\\_64962.rss2](http://presseportal.de/rss/pm_64962.rss2)